Compass Pathways Sees Unusually Large Options Volume (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the target of unusually large options trading on Monday. Stock traders bought 8,121 call options on the stock. This represents an increase of approximately 81% compared to the typical daily volume of 4,494 call options.

Compass Pathways Stock Up 3.8%

Compass Pathways stock traded up $0.39 during midday trading on Monday, hitting $10.76. The stock had a trading volume of 3,533,884 shares, compared to its average volume of 3,554,700. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.45 billion, a P/E ratio of -3.40 and a beta of 2.39. Compass Pathways has a 12 month low of $2.25 and a 12 month high of $11.65. The business has a fifty day moving average price of $7.23 and a 200 day moving average price of $6.74.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Research analysts predict that Compass Pathways will post -0.99 EPS for the current year.

Institutional Trading of Compass Pathways

Institutional investors and hedge funds have recently made changes to their positions in the stock. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter worth approximately $47,000. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter worth approximately $41,000. Parallel Advisors LLC raised its position in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares during the period. Finally, North Star Investment Management Corp. raised its position in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after purchasing an additional 7,000 shares during the period. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Maxim Group boosted their price target on Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday. B. Riley Financial assumed coverage on Compass Pathways in a research note on Friday, April 24th. They issued a “buy” rating and a $17.00 price target on the stock. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Morgan Stanley boosted their price target on Compass Pathways from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Wall Street Zen upgraded Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Compass Pathways has an average rating of “Moderate Buy” and an average price target of $20.58.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.